Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
IDeate-Esophageal01 trial: what clinicians have said so far
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- NCT06644781 ↗
- Recruiting
- Daiichi Sankyo
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on IDeate-Esophageal01 (ifinatamab deruxtecan in pretreated advanced or metastatic esophageal squamous cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IDeate-Esophageal01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Ifinatamab deruxtecan; Docetaxel; Paclitaxel; Irinotecan hydrochloride (HCl)
- Arms
- I-DXd · Experimental
- Investigator's Choice of Chemotherapy (ICC) · Active comparator
- Enrollment
- 510 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Daiichi Sankyo with Merck Sharp & Dohme LLC
- Start
- Mar 27, 2025
- Primary completion
- Jun 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06644781 · updated Oct 26, 2026